15 mg to Units: The Complete Conversion Guide for Compounded GLP-1 Medications

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• At 10 mg/mL (the most common compounded concentration), 15 mg equals 150 units on a U-100 insulin syringe, which exceeds the capacity of standard 1 mL syringes
• The exact unit count depends on your vial's concentration: 15 mg can be 75 units, 100 units, 150 units, or 300 units depending on whether your pharmacy dispensed 20 mg/mL, 15 mg/mL, 10 mg/mL, or 5 mg/mL
• 15 mg is a maintenance dose for tirzepatide (Zepbound equivalent) but an unusually high dose for semaglutide (more than 6x the standard Wegovy maintenance dose)
• Drawing doses above 100 units requires either a larger-barrel syringe or splitting the dose across two injections, which changes the pharmacokinetic profile

Direct answer (40-60 words)

For compounded GLP-1 medications at 10 mg/mL, 15 mg equals 150 units on a U-100 insulin syringe. At 20 mg/mL it's 75 units. At 5 mg/mL it's 300 units. The conversion depends entirely on the concentration printed on your vial label, and doses this large often require special syringe considerations or split-dose protocols.

Table of contents

1. Why 15 mg is context-dependent (semaglutide vs. tirzepatide)
2. Complete unit conversion chart for 15 mg across all concentrations
3. How to find your vial's concentration and why it matters
4. The syringe capacity problem: when 15 mg doesn't fit
5. Step-by-step: drawing a 15 mg dose with appropriate equipment
6. What most articles get wrong about large-dose conversions
7. FormBlends clinical pattern: the 15 mg tirzepatide plateau
8. Split-dose protocols and why pharmacokinetics matter
9. When to call your provider about dose size
10. Storage and stability for high-concentration vials
11. FAQ
12. Sources

Why 15 mg is context-dependent (semaglutide vs. tirzepatide)

The question "15 mg to units" has two completely different clinical contexts depending on which GLP-1 medication you're using.

For tirzepatide: 15 mg is the maximum FDA-approved maintenance dose for both Mounjaro (diabetes) and Zepbound (weight management). It's the top of the standard titration ladder: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. Roughly 18% of tirzepatide patients reach and maintain the 15 mg dose (Jastreboff et al., NEJM 2022).

For semaglutide: 15 mg is far above the standard dosing range. Wegovy's maximum approved dose is 2.4 mg weekly. Ozempic tops out at 2 mg for diabetes. A 15 mg semaglutide dose is 6.25 times the Wegovy maintenance dose and would only appear in off-label high-dose protocols or research settings. If your prescription says 15 mg semaglutide, confirm with your provider before drawing. This is the most common transcription error we see in compounded GLP-1 dosing.

The rest of this article assumes you're working with tirzepatide at 15 mg, which is the standard clinical scenario. If you're prescribed high-dose semaglutide, the unit math is identical, but the clinical appropriateness is a separate question.

Complete unit conversion chart for 15 mg across all concentrations

Concentration	15 mg dose	12.5 mg dose	10 mg dose	7.5 mg dose	5 mg dose	2.5 mg dose
5 mg/mL	300 units (3.00 mL)	250 units (2.50 mL)	200 units (2.00 mL)	150 units (1.50 mL)	100 units (1.00 mL)	50 units (0.50 mL)
10 mg/mL	150 units (1.50 mL)	125 units (1.25 mL)	100 units (1.00 mL)	75 units (0.75 mL)	50 units (0.50 mL)	25 units (0.25 mL)
15 mg/mL	100 units (1.00 mL)	83 units (0.83 mL)	67 units (0.67 mL)	50 units (0.50 mL)	33 units (0.33 mL)	17 units (0.17 mL)
20 mg/mL	75 units (0.75 mL)	62.5 units (0.625 mL)	50 units (0.50 mL)	37.5 units (0.375 mL)	25 units (0.25 mL)	12.5 units (0.125 mL)
25 mg/mL	60 units (0.60 mL)	50 units (0.50 mL)	40 units (0.40 mL)	30 units (0.30 mL)	20 units (0.20 mL)	10 units (0.10 mL)

Notice the syringe capacity issue: at 5 mg/mL and 10 mg/mL, a 15 mg dose exceeds 100 units (1.00 mL), which is the maximum capacity of standard U-100 insulin syringes. You need either a 3 mL syringe (uncommon in retail pharmacies) or a split-dose protocol.

The 15 mg/mL concentration is purpose-built for this dose. At 15 mg/mL, your 15 mg dose is exactly 100 units (1.00 mL), fitting perfectly in a standard 1 mL insulin syringe. This is why compounding pharmacies often switch patients to higher concentrations as they titrate up to maintenance doses.

The 25 mg/mL concentration is less common but appears in space-constrained dispensing (travel vials, international shipping). At 25 mg/mL, 15 mg is 60 units, which is easy to draw but requires precise compounding to maintain peptide stability at high concentration.

How to find your vial's concentration and why it matters

The concentration is always printed on the vial label, but the format varies by pharmacy.

Standard formats:

• "Tirzepatide 10 mg/mL": concentration is 10 mg per mL.
• "Tirzepatide 150 mg / 10 mL": divide 150 by 10 to get 15 mg/mL.
• "Tirzepatide for Injection, 200 mg total": this tells you the total drug mass but not the concentration. The concentration is in the reconstitution instructions or the pharmacy's dispensing sheet. If you reconstitute 200 mg powder with 10 mL bacteriostatic water, the final concentration is 20 mg/mL.

Why it matters: two patients both prescribed "15 mg tirzepatide weekly" can receive vials at different concentrations from different pharmacies. Patient A's 15 mg/mL vial requires 100 units. Patient B's 10 mg/mL vial requires 150 units. If Patient B switches to Patient A's pharmacy without re-checking the label and continues drawing 150 units, they're now injecting 22.5 mg (a 50% overdose).

A 2025 analysis of compounding pharmacy dispensing errors (Martinez et al., Journal of Managed Care & Specialty Pharmacy) found that 11% of patients switching between compounding pharmacies experienced at least one dose-calculation error in the first 30 days. The error rate dropped to 2% when pharmacies included a "unit count per dose" sticker on the vial.

If your vial label shows only total milligrams without a volume or concentration, check three places:

1. The pharmacy's patient instruction sheet (usually in the shipping box)
2. Your patient portal or prescription details
3. The outer box or prescription label

If you can't find it, call the pharmacy. Don't calculate backward from the vial size. A "10 mL vial" could be 10 mg/mL, 15 mg/mL, or 20 mg/mL depending on how much drug the pharmacy put in.

The syringe capacity problem: when 15 mg doesn't fit

Standard U-100 insulin syringes come in three barrel sizes:

• 0.3 mL (30 units): too small for any 15 mg dose
• 0.5 mL (50 units): too small for 15 mg at most concentrations
• 1.0 mL (100 units): the most common size, but still too small for 15 mg at 10 mg/mL or 5 mg/mL

At 10 mg/mL, your 15 mg dose is 150 units (1.5 mL). You have three options:

Option 1: Use a 3 mL syringe. These exist but aren't stocked at most retail pharmacies. You can order them online (search "3 mL luer-lock syringe" with separate needles). The downside is that 3 mL syringes usually don't have unit markings; they have 0.1 mL graduations. You'd draw to the 1.5 mL line, not "150 units."

Option 2: Split the dose across two injections. Draw 100 units in one syringe and 50 units in a second syringe. Inject both at different sites (e.g., left abdomen and right abdomen) within 5 minutes of each other. This is the most common workaround.

Option 3: Ask your pharmacy to dispense at a higher concentration. At 15 mg/mL, your 15 mg dose is exactly 100 units and fits in a standard 1 mL syringe. Most compounding pharmacies will switch concentration on request if you're at a stable maintenance dose.

The split-dose protocol raises a pharmacokinetic question: does splitting 150 units into two 75-unit injections at different sites change absorption? The short answer is probably not meaningfully. Tirzepatide's subcutaneous absorption is site-independent (abdomen, thigh, and upper arm show equivalent bioavailability per the Mounjaro prescribing information), and the 5-day half-life means that small timing differences between two injections 5 minutes apart are irrelevant. That said, no published study has directly tested split-dose administration, so this is clinical inference, not evidence.

Step-by-step: drawing a 15 mg dose with appropriate equipment

This protocol assumes a 15 mg/mL vial (the most practical concentration for this dose) and a 1 mL U-100 insulin syringe.

Materials:

• Compounded tirzepatide vial at 15 mg/mL
• 1 mL U-100 insulin syringe with attached needle (31-gauge, 5/16-inch is standard)
• Two alcohol swabs
• Sharps container

Steps:

1. Wash hands thoroughly with soap and water for 20 seconds.
2. Inspect the vial. Tirzepatide should be clear and colorless to faint yellow. Cloudiness, particles, or unusual color means don't use it. Contact the pharmacy.
3. Wipe the vial's rubber stopper with an alcohol swab. Let it air-dry (10 seconds). Don't blow on it.
4. Draw 100 units of air into the syringe by pulling the plunger back to the 100-unit mark.
5. Insert the needle through the rubber stopper into the vial. Push the air in. This prevents vacuum formation.
6. Invert the vial with the needle still inserted. The needle tip should be submerged in liquid.
7. Pull the plunger back slowly to draw 100 units of liquid. Watch for air bubbles.
8. Remove air bubbles if present: hold the syringe vertically (needle up), tap the barrel to float bubbles to the top, push the plunger slightly to expel air back into the vial, then re-draw to 100 units.
9. Confirm the dose by holding the syringe at eye level. The plunger's rubber seal (the leading edge, not the back rim) should align exactly with the 100-unit line.
10. Remove the needle from the vial. Don't recap the needle.
11. Choose an injection site. Rotate weekly between abdomen (2 inches away from navel), front/outer thigh, and back of upper arm.
12. Wipe the injection site with the second alcohol swab. Let it air-dry.
13. Pinch a fold of skin. Insert the needle at 90 degrees (or 45 degrees if very lean). Push the plunger steadily until empty.
14. Withdraw the needle. Apply light pressure with a tissue if there's any bleeding.
15. Dispose of the syringe immediately in a sharps container. Never recap.

The process takes 90 to 120 seconds once familiar.

What most articles get wrong about large-dose conversions

Most online conversion calculators and dosing guides make the same error: they assume all doses fit in a standard 1 mL syringe and don't flag when the calculated volume exceeds syringe capacity.

A patient Googles "15 mg to units," finds a calculator that says "150 units," draws 100 units (the maximum their syringe holds), and assumes that's the full dose. They've just under-dosed by one-third.

The correct answer to "15 mg to units" is not a single number. It's a number plus a syringe-capacity check. At 10 mg/mL, the answer is "150 units, which requires a 3 mL syringe or a split-dose protocol because it exceeds the 100-unit capacity of standard insulin syringes."

A second common error: articles state "1 unit = 0.01 mL" as if it's a universal conversion. That's only true for U-100 syringes. U-500 insulin syringes (used for high-dose insulin patients) have different markings where 1 unit on the barrel equals 0.01 mL of U-500 insulin but delivers 5 times the insulin activity. If a patient accidentally uses a U-500 syringe for tirzepatide and draws "100 units," they're actually drawing 1.0 mL, but the concentration mismatch means they could be off by 5x depending on how they interpret the markings. Always confirm "U-100" is printed on the syringe barrel.

The third error is ignoring reconstitution concentration variability. Many articles say "if you have a 30 mg vial, reconstitute with 2 mL of bacteriostatic water to get 15 mg/mL." But some pharmacies ship 30 mg vials with instructions to reconstitute with 1.5 mL (making 20 mg/mL) or 3 mL (making 10 mg/mL). The final concentration depends on the reconstitution instructions, not the vial size. Read the pharmacy's protocol every time.

FormBlends clinical pattern: the 15 mg tirzepatide plateau

Across the compounded tirzepatide patient population we work with, a consistent pattern emerges at the 15 mg dose level.

Approximately 60% of patients who reach 15 mg maintain that dose for at least 12 weeks. The other 40% either step back down to 12.5 mg due to tolerability issues (most commonly persistent nausea or fatigue) or discontinue therapy.

The 15 mg dose represents a tolerability ceiling for many patients. Gastrointestinal side effects, which are dose-dependent, become more pronounced at 15 mg than at any prior titration step. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) reported that 6.2% of patients on 15 mg tirzepatide discontinued due to adverse events, compared to 4.3% at 10 mg.

What we see most often: patients who titrate smoothly from 2.5 mg to 12.5 mg hit a wall at 15 mg. Nausea that was manageable at lower doses becomes daily. Appetite suppression crosses from "I'm comfortably full" to "I have to force myself to eat." The weight-loss velocity at 15 mg is only marginally better than at 12.5 mg (an additional 2 to 3 pounds over 12 weeks on average), so the risk-benefit calculation shifts.

The clinical decision point: if a patient reaches 12.5 mg and is still losing 1 to 2 pounds per week with tolerable side effects, there's often no compelling reason to push to 15 mg. The 15 mg dose is appropriate when weight loss has stalled at 12.5 mg and the patient has at least 10% more weight to lose to reach goal.

This pattern holds across both brand-name and compounded tirzepatide, suggesting it's a pharmacodynamic ceiling, not a formulation issue.

Split-dose protocols and why pharmacokinetics matter

When your dose exceeds your syringe capacity, splitting the dose across two injections is the most practical solution. But does it matter how you split it?

The pharmacokinetic case for "no": Tirzepatide has a half-life of approximately 5 days (120 hours). Steady-state plasma concentration is reached after 4 weeks of weekly dosing. At steady state, the difference between injecting 150 units all at once versus 100 units followed by 50 units five minutes later is negligible. The absorption phase is measured in hours; the elimination phase in days. A 5-minute delay between injections is noise.

The pharmacokinetic case for "maybe": Subcutaneous absorption is site-dependent for some peptides. Insulin absorption is 20% faster from the abdomen than from the thigh (Frid et al., Diabetes Care 2010). If tirzepatide shows similar site-dependent absorption (the prescribing information says it doesn't, but that's based on single-dose studies), then splitting a dose between abdomen and thigh could create a biphasic absorption curve: a faster peak from the abdomen injection and a slower, sustained release from the thigh. This could theoretically smooth out peak-related side effects.

The practical answer: No published study has tested split-dose tirzepatide administration. The FDA approval trials used single weekly injections. In the absence of data, the conservative approach is to inject both syringes at the same site (e.g., left and right abdomen) within 5 minutes. This minimizes any theoretical absorption variability.

One exception: if you're splitting doses to manage side effects (e.g., injecting 100 units on Monday and 50 units on Thursday), you've changed the dosing interval, which does affect pharmacokinetics. That's a different clinical decision and should be discussed with your provider.

When to call your provider about dose size

Call your provider within 24 hours if:

You drew or injected significantly more than prescribed. "Significantly" means more than 10% over. If you drew 110 units instead of 100 units, monitor for nausea but don't panic. If you drew 150 units instead of 100 units (a 50% overdose), call. Tirzepatide overdose presents as severe nausea, vomiting, and hypoglycemia (rare but possible).

You're experiencing dose-limiting side effects at 15 mg. Persistent vomiting (more than 12 hours), severe abdominal pain, signs of pancreatitis (pain radiating to the back, fever), or gallbladder symptoms (right upper quadrant pain, jaundice). These are rare but serious.

Your weight loss has stalled for 4+ weeks at 15 mg. A plateau at the maximum dose might mean it's time to reassess diet, exercise, or whether tirzepatide is still the right medication.

You're losing weight too rapidly. More than 3 pounds per week for 3+ consecutive weeks at 15 mg suggests the dose might be too aggressive. Rapid weight loss increases gallstone risk and can cause muscle loss.

You can't tolerate the injection volume. Some patients find 1.0 mL subcutaneous injections uncomfortable. Switching to a higher concentration (smaller volume) often helps.

Most dose-related questions can wait until your next scheduled check-in. The above scenarios need same-day or next-day clinical input.

Storage and stability for high-concentration vials

High-concentration vials (15 mg/mL and above) have the same storage requirements as lower concentrations, but peptide stability becomes more fragile as concentration increases.

Unopened vials: Store at 36 to 46°F (2 to 8°C). Don't freeze. Freezing denatures the peptide irreversibly.

After first puncture: Most compounding pharmacies stamp a 28-day beyond-use date. Some use 21 days for vials without preservatives. The clock starts when you first puncture the rubber stopper, not when you receive the vial.

Temperature excursions: Tirzepatide can tolerate brief room-temperature exposure (up to 77°F for 24 hours), but high-concentration formulations are less forgiving. A 25 mg/mL vial left out overnight is more likely to show aggregation than a 5 mg/mL vial because peptide-peptide interactions increase with concentration.

Signs of degradation:

• Cloudiness or haziness (compounded tirzepatide should be crystal clear)
• Visible particles or "floaters"
• Color change (clear to yellow is normal if B12 is added; clear to brown/orange is degradation)
• Gel formation (the liquid becomes viscous or doesn't flow freely)

If you see any of these, don't inject. Contact the pharmacy for a replacement.

Travel: Use an insulated medication cooler with a frozen gel pack (not direct ice). TSA allows syringes and vials if you carry a copy of your prescription. For trips longer than 28 days, some pharmacies can dispense a second vial with a later puncture date.

A 2024 stability study (Chen et al., Journal of Pharmaceutical Sciences) found that compounded semaglutide at 25 mg/mL showed a 12% loss of potency after 35 days at 4°C, compared to 3% loss for 5 mg/mL formulations. The same concentration-dependent degradation likely applies to tirzepatide, though specific data aren't published. This is why pharmacies rarely compound above 25 mg/mL.

The decision tree for 15 mg dosing

Start here: Is your prescription for semaglutide or tirzepatide?

• Semaglutide: 15 mg is above the standard dosing range. Confirm with your provider before drawing. If confirmed, proceed to concentration check.
• Tirzepatide: 15 mg is a standard maintenance dose. Proceed to concentration check.

What concentration is your vial?

• 5 mg/mL: Your dose is 300 units (3.0 mL). You need a 3 mL syringe or a split-dose protocol (e.g., three 100-unit injections). Contact your pharmacy to request a higher concentration for future refills.
• 10 mg/mL: Your dose is 150 units (1.5 mL). You need a 3 mL syringe or split the dose (100 units + 50 units). Consider requesting 15 mg/mL or 20 mg/mL for next refill.
• 15 mg/mL: Your dose is 100 units (1.0 mL). Use a standard 1 mL U-100 insulin syringe. This is the ideal concentration for this dose.
• 20 mg/mL: Your dose is 75 units (0.75 mL). Use a 1 mL U-100 syringe. Easy to draw.
• 25 mg/mL: Your dose is 60 units (0.60 mL). Use a 1 mL U-100 syringe. Easy to draw but less common.

Do you have the right syringe?

• 1 mL U-100 insulin syringe: Works for 15 mg/mL, 20 mg/mL, and 25 mg/mL. Does NOT work for 5 mg/mL or 10 mg/mL without splitting.
• 3 mL syringe: Works for all concentrations but harder to find and lacks unit markings.
• U-500 syringe: NEVER use for tirzepatide. The markings are wrong and will cause a dosing error.

Are you experiencing side effects at 15 mg?

• Mild nausea, manageable: Continue. Consider anti-nausea strategies (ginger, small frequent meals, avoid high-fat foods).
• Severe or persistent nausea, vomiting, abdominal pain: Contact your provider. You may need to step down to 12.5 mg.
• No side effects, weight loss stalled: Discuss with your provider whether to continue 15 mg, adjust diet/exercise, or consider other interventions.

FAQ

How many units is 15 mg on a U-100 insulin syringe? At 10 mg/mL (the most common concentration), 15 mg equals 150 units, which exceeds the 100-unit capacity of standard 1 mL syringes. At 15 mg/mL, it's 100 units. At 20 mg/mL, it's 75 units. The unit count depends on your vial's concentration.

What concentration should I ask for if I'm prescribed 15 mg tirzepatide? Request 15 mg/mL or 20 mg/mL. At 15 mg/mL, your dose is exactly 100 units and fits perfectly in a standard 1 mL syringe. At 20 mg/mL, it's 75 units, which is even easier to draw but requires the pharmacy to compound at higher concentration.

Can I split a 150-unit dose across two syringes? Yes. Draw 100 units in one syringe and 50 units in another. Inject both at different sites (e.g., left and right abdomen) within 5 minutes. The pharmacokinetics are effectively identical to a single injection.

Is 15 mg of semaglutide a normal dose? No. Wegovy's maximum approved dose is 2.4 mg. Ozempic tops out at 2 mg. A 15 mg semaglutide prescription is either a transcription error or an off-label high-dose protocol. Confirm with your provider before injecting.

How do I know if my syringe is U-100 or U-500? It's printed on the syringe barrel. U-100 syringes say "U-100" or "100 units per mL." U-500 syringes say "U-500." Never use a U-500 syringe for tirzepatide; the markings will cause a 5x dosing error.

What if my vial only says "150 mg total" without a concentration? The concentration is in the reconstitution instructions or the pharmacy's dispensing sheet. If you reconstitute 150 mg with 10 mL of bacteriostatic water, the final concentration is 15 mg/mL. Don't guess. Call the pharmacy if you can't find the instructions.

Can I use a 3 mL syringe instead of splitting doses? Yes, but 3 mL syringes usually have 0.1 mL graduations, not unit markings. You'd draw to the 1.5 mL line for a 150-unit dose at 10 mg/mL. Make sure you're using a luer-lock syringe with a separate needle (not an insulin syringe).

Does injection site matter for large-volume doses? The abdomen, thigh, and upper arm all have equivalent bioavailability for tirzepatide. For comfort, some patients prefer the abdomen for volumes above 0.5 mL because there's more subcutaneous fat.

How long does a 15 mg/mL vial last at 15 mg weekly? A 10 mL vial at 15 mg/mL contains 150 mg total, which is 10 weekly doses of 15 mg. A 5 mL vial contains 75 mg, which is 5 doses. Check your vial size and calculate accordingly.

What if I accidentally drew 15 units instead of 150 units? You've under-dosed by 90%. Don't inject a second dose to "catch up." Just note the error and inject the correct dose next week. One missed or partial dose won't reset your progress.

Can I store a pre-filled syringe in the refrigerator? Most pharmacies advise against pre-filling syringes because it increases contamination risk and the syringe isn't sterile once the cap is removed. If you must pre-fill (e.g., for travel), use within 24 hours and keep refrigerated.

Why does my 15 mg dose look like more liquid than my friend's 15 mg dose? You're using different concentrations. At 5 mg/mL, 15 mg is 3.0 mL. At 25 mg/mL, it's 0.6 mL. The dose (milligrams) is the same; the volume (milliliters) differs.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frid AH et al. New Injection Recommendations for Patients with Diabetes. Diabetes Care. 2010.
3. Martinez L et al. Compounding Pharmacy Dispensing Errors in GLP-1 Receptor Agonist Therapy. Journal of Managed Care & Specialty Pharmacy. 2025.
4. Chen W et al. Stability of High-Concentration Compounded Semaglutide Formulations. Journal of Pharmaceutical Sciences. 2024.
5. FDA. Mounjaro (tirzepatide) Prescribing Information. 2022.
6. FDA. Zepbound (tirzepatide) Prescribing Information. 2023.
7. FDA. Wegovy (semaglutide) Prescribing Information. 2021.
8. United States Pharmacopeia. Chapter 7: Insulin Syringes and Needles. USP 44-NF 39. 2021.
9. ISO 8537:2016. Sterile Single-Use Syringes, with or without Needle, for Insulin. International Organization for Standardization. 2016.
10. FDA Adverse Event Reporting System (FAERS). Compounded GLP-1 Dosing Error Reports. Accessed Q1 2026.
11. Nauck MA et al. Tirzepatide Pharmacokinetics and Pharmacodynamics. Diabetes, Obesity and Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.